Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02603445 | Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL | PHASE1 | COMPLETED | 20 | — | — | Nov 16, 2015 | Jul 10, 2018 | Feb 24, 2020 | 7 | United States, Austria +2 |
Characterized by Frequency, severity and seriousness of AEs, lab abnormalities and other safety parameters such as electrocardiogram (ECG) changes
| Arm | Type | Description |
|---|---|---|
| Follicular lymphoma (FL) | EXPERIMENTAL | - |
| Mantle cell lymphoma (MCL) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BCL201 | DRUG | - |
| Idelalisib | DRUG | - |
Inclusion Criteria: * Histologically confirmed diagnosis of FL or MCL according to WHO 2008 * Relapsed or refractory with at least one (FL) or two (MCL), but not more than four, prior lines of antineoplastic regimens. * Either FDG-avid on FDG-PET or measurable disease by CT on cross sectional imagi...